MFDS to Support SMEs in Patent Challenges... Up to 30 Million Won Per Company

In a significant move to bolster its domestic pharmaceutical industry, South Korea's Ministry of Food and Drug Safety (MFDS) has launched a new initiative to support small and medium-sized enterprises (SMEs) in their efforts to challenge existing drug patents. This program, titled the '2026 Pharmaceutical Patent Response Strategy Consulting Support Project,' signifies a proactive approach to fostering innovation and competition within the sector.

The MFDS recognizes the substantial hurdles that patent protection can pose for smaller companies seeking to develop and market generic or biosimilar drugs. By providing consulting services and strategic guidance, the ministry aims to equip these SMEs with the necessary tools to navigate complex patent landscapes. This includes support for actions such as patent invalidation trials and non-infringement claims, thereby leveling the playing field and encouraging the development of more affordable medicines.

This initiative is particularly crucial for South Korea's economic strategy, which emphasizes technological advancement and self-sufficiency in key industries. By empowering local pharmaceutical companies, the MFDS not only promotes business growth but also contributes to public health by potentially increasing access to essential medications. The program underscores the government's commitment to nurturing its homegrown industries and ensuring they can compete effectively on both domestic and international stages. The application period, running until June 7th, invites eligible companies to leverage this valuable support system.